Please login to the form below
Rybelsus
This page shows the latest Rybelsus news and features for those working in and with pharma, biotech and healthcare.
Novo Nordisk’s type 2 diabetes drug approved by FDA as first-line option
By taking Rybelsus first, people with type 2 diabetes, in conjunction with their care teams, are now able to utilise this medicine early in their diabetes treatment journeys.”. ... The FDA’s 2019 decision on Rybelsus was based on the results from ten
Latest news
-
Lilly’s tirzepatide shows superiority over Novo’s semaglutide in type 2 diabetes trial
Also within Novo’s roster is an oral formulation of semaglutide – marketed under the Rybelsus brand name – that is authorised for the treatment of type 2 diabetes.
-
Novo Nordisk set to acquire Emisphere Technology for $1.8bn
Following the acquisition deal completion, Novo will pick up Emisphere’s drug delivery technology – Eligen SNAC – which it uses in its oral diabetes drug Rybelsus (oral semaglutide). ... Novo won US Food and Drug Administration (FDA) approval for
-
Lilly’s Trulicity scores CV reduction indication in the US
Novo also has Rybelsus – oral semaglutide – in its arsenal, and analysts at Pareto Securities have suggested that demand for an oral alternative GLP-1 could make the drug a $5.4bn
-
New drugs drive Novo Nordisk despite insulin price pressures
Novo also reported sales of DKK50m for its recently launched oral semaglutide product Rybelsus in the quarter – the company has said it is encouraged by the early performance of the drug, ... The Rybelsus launch in the US is off to a good start, and
-
Givlaari, Rybelsus lead crowded CHMP recommendations
Joining Givlaari with a positive recommendation was Rybelsus (semaglutide), Novo Nordisk’s once-daily oral formulation of its injectable GLP-1 agonist semaglutide. ... In Novo’s Pioneer programme of the drug, people treated with Rybelsus achieved
More from news
Approximately 5 fully matching, plus 4 partially matching documents found.
Latest Intelligence
-
On our best behaviour
Meanwhile, Novo Nordisk has launched Rybelsus (semaglutide) oral tablets to improve control of blood sugar – but specifically alongside diet and exercise.
-
Cortellis Drugs to Watch in 2020 report
7. NovoNordisk’s Rybelsus is an oral once-daily formulation of semaglutide, a long-acting glucagon-like peptide (GLP)-1 analog. ... Rybelsus is available in the US to improve glycaemic control in adults with type 2 diabetes.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- EU outlines measures to mitigate antibiotic shortage across Europe
- Europe’s cancer community publishes new report on transforming patient care
- Meeting healthcare’s rising challenges
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Tidepool’s automated insulin dosing app for type 1 diabetes gets FDA approval
- UK to introduce new regulatory framework for point of care manufacturing
- Navigating the patient experience to improve retention of clinical trial participants
- Europe’s cancer community publishes new report on transforming patient care
- Alzheimer’s Research UK welcomes government’s pledge to tackle dementia crisis
- World Health Organization releases latest set of COVID-19 guidelines
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- EU to revise pharmaceuticals law amid antibiotic shortages
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Why everyone in pharma is bending over backwards to be agile
PMHub
Bedrock Healthcare Communications
Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical...
Latest intelligence
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
- Report gives insights to address gaps in HCP engagement
- How does Pharma-HCP engagement need to evolve in today's digital landscape?...
